NextCure, Inc. (NXTC): Price and Financial Metrics

NextCure, Inc. (NXTC): $1.74

0.06 (+3.79%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Add NXTC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#151 of 380

in industry

NXTC Price/Volume Stats

Current price $1.74 52-week high $5.27
Prev. close $1.68 52-week low $1.16
Day low $1.67 Volume 34,100
Day high $1.80 Avg. volume 83,591
50-day MA $1.61 Dividend yield N/A
200-day MA $2.07 Market Cap 48.43M

NXTC Stock Price Chart Interactive Chart >


NextCure, Inc. (NXTC) Company Bio


NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.


NXTC Latest News Stream


Event/Time News Detail
Loading, please wait...

NXTC Latest Social Stream


Loading social stream, please wait...

View Full NXTC Social Stream

Latest NXTC News From Around the Web

Below are the latest news stories about NEXTCURE INC that investors may wish to consider to help them evaluate NXTC as an investment opportunity.

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | May 11, 2023

NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcur

Yahoo | May 9, 2023

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs First patient dosed with NC525 (LAIR-1 mAb) in a Phase 1 trial in acute myeloid leukemia (AML) Cash of approximately $145 million expected to fund operations into mid-2025 BELTSVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases

Yahoo | May 4, 2023

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure

Yahoo | April 11, 2023

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

Clinical data updates expected in 2023 for all three programsNC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML)Ended 2022 with approximately $160 million in cash that is expected to fund operations into mid-2025 BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related dise

Yahoo | March 2, 2023

Read More 'NXTC' Stories Here

NXTC Price Returns

1-mo 9.43%
3-mo 16.00%
6-mo 24.29%
1-year -58.27%
3-year -93.53%
5-year N/A
YTD 23.40%
2022 -76.50%
2021 -44.95%
2020 -80.65%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!